bioRxivCancer BiologyPreprint
Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies
Abstract
BACKGROUNDDespite its importance in the clinical management of ovarian cancer, the CA125 biomarker--located on the mucin protein MUC16--is still not completely understood. Questions remain about MUC16s function and structure, specifically the identity and location of the CA125 epitopes. OBJECTIVEThe goal of this study was to characterize the interaction of individual recombinant repeats from the tandem repeat domain of MUC16 with antibodies used in the clinical CA125 II test. METHODSUsing E. coli expression, we isolated nine repeats from the putative antigenic domain of CA125. Amino acid composition of recombinant repeats was confirmed by high-resolution mass spectrometry. We characterized the binding of four antibodies--OC125, M11, "OC125-like," and "M11-like"--to nine recombinant repeats using Western blotting, indirect enzyme-linked immunosorbent assay (ELISA), and localized surface plasmon resonance (SPR) spectroscopy. RESULTSEach recombinant repeat was recognized by a different combination of CA125 antibodies. OC125 and "OC125-like" antibodies did not bind the same set of recombinant repeats, nor did M11 and "M11-like" antibodies. CONCLUSIONSCharacterization of the interactions between MUC16 recombinant repeats and CA125 antibodies will contribute to ongoing efforts to identify the CA125 epitopes and improve our understanding of this important biomarker.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Reverse engineering the anti-MUC1 hybridoma antibody 139H2 by mass spectrometry-based de novo sequencing
W. Peng, K. C. A. P. Giesbers, … J. Snijder·bioRxiv·Jul 5, 2023
- Integrated Cytotoxic and Safety Mechanism of IMV-M (TM), a MUC16 x DR5 Bispecific Antibody
Victor S. Goldmacher, Iosif M. Gershteyn·bioRxiv·Feb 11, 2026
- A humanized 16A antibody conjugated with DNA topoisomerase I inhibitors, targeting a GSTA glycosite-signature epitope.
Yu He, Zhaohui Ji, … Dapeng Zhou·bioRxiv·Mar 22, 2025
- The landscape of high-affinity human antibodies against intratumoral antigens
G. Rakocevic, I. Gotlova, … D. Biasci·bioRxiv·Feb 6, 2021
- Targeting the TRA-1-60 Glycoepitope Enables Selective ImmunoPET Imaging of Ovarian Cancer
Sajmina Khatun, Alexandra Fox, … Nerissa T. Viola·bioRxiv·Aug 17, 2026
- An antibody drug conjugate targeting a GSTA glycosite-signature epitope of mucin1 expressed by non-small cell lung cancer